JP2014511857A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511857A5
JP2014511857A5 JP2014503275A JP2014503275A JP2014511857A5 JP 2014511857 A5 JP2014511857 A5 JP 2014511857A5 JP 2014503275 A JP2014503275 A JP 2014503275A JP 2014503275 A JP2014503275 A JP 2014503275A JP 2014511857 A5 JP2014511857 A5 JP 2014511857A5
Authority
JP
Japan
Prior art keywords
protein
composition
cancer
gcmaf
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014503275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511857A (ja
JP6113712B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2012/000159 external-priority patent/WO2012137199A1/en
Publication of JP2014511857A publication Critical patent/JP2014511857A/ja
Publication of JP2014511857A5 publication Critical patent/JP2014511857A5/ja
Application granted granted Critical
Publication of JP6113712B2 publication Critical patent/JP6113712B2/ja
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014503275A 2011-04-07 2012-04-05 医薬組成物のマクロファージ活性化因子 Ceased JP6113712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472642P 2011-04-07 2011-04-07
US61/472,642 2011-04-07
PCT/IL2012/000159 WO2012137199A1 (en) 2011-04-07 2012-04-05 Macrophage activating factor for pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2014511857A JP2014511857A (ja) 2014-05-19
JP2014511857A5 true JP2014511857A5 (enExample) 2015-05-14
JP6113712B2 JP6113712B2 (ja) 2017-04-12

Family

ID=46968677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503275A Ceased JP6113712B2 (ja) 2011-04-07 2012-04-05 医薬組成物のマクロファージ活性化因子

Country Status (7)

Country Link
US (3) US20140030215A1 (enExample)
EP (1) EP2694088B1 (enExample)
JP (1) JP6113712B2 (enExample)
CN (1) CN103547280B (enExample)
AU (1) AU2012240945B2 (enExample)
CA (1) CA2832487A1 (enExample)
WO (1) WO2012137199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913115A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
WO2018025270A1 (en) * 2016-08-04 2018-02-08 Efranat Ltd. Enriched modified vitamin d binding protein compositions and use thereof
WO2022124331A1 (ja) * 2020-12-08 2022-06-16 再生ファーマ株式会社 マクロファージ活性化剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5177002A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US6096216A (en) 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
US5814225A (en) 1994-06-09 1998-09-29 Shanbrom Technologies Llc Iodinated gel filtration media for disinfecting protein solutions
US6410269B1 (en) 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
WO2002058589A2 (en) * 2000-11-09 2002-08-01 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
DE60335553D1 (de) * 2002-07-03 2011-02-10 Illumigen Biosciences Inc Verfahren und zusammensetzungen zur diagnose eines leberzellenkarzinoms
US20070275001A1 (en) * 2004-02-05 2007-11-29 Arizona Board Of Regents Rational Design and Engineering of Proteins and Peptides for Immunomodulation
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
IN2012DN02200A (enExample) 2009-08-22 2015-08-21 Charles Knezevich

Similar Documents

Publication Publication Date Title
EP4378962A3 (en) Anti-cancer fusion polypeptide
UA109108C2 (uk) Антитіло до pd-l1 та його застосування для посилення функції t-клітин
MX2017014716A (es) Polipeptido de fusion anti-cancer.
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
UA106369C2 (ru) Способ очистки рекомбинантного фсг
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
WO2016187220A3 (en) Anti-ror1 antibodies
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
JP2014527996A5 (enExample)
BR112015022288A2 (pt) 2-aminopirimidin-6-onas e análogos exibindo atividades anticâncer e antiproliferativas, sua composição faramcêutica e seus usos
NO20051575L (no) Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet
WO2013061083A3 (en) Therapeutic agents and uses thereof
SG10201906859PA (en) Novel proteins specific for angiogenesis
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
JP2014511857A5 (enExample)
ATE542819T1 (de) Substituierte pyrroloä2, 3-bü- und pyrazoloä3, 4- büpyridine als adenosin rezeptor liganden
TN2014000112A1 (en) Ep1 receptor ligands
EP4252755A3 (en) Therapeutic compounds
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
CN110461836A (zh) 一种选择性抑制激酶化合物及其用途
EP1971338B8 (en) Combination of zd6474 and pemetrexed
AU2017265377A1 (en) Tetrahydropyran and Thiopyran derivatives having multimodal activity against pain
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
WO2011003935A9 (en) Parathyroid hormone related protein antagonists